NCI National Clinical Trials Network-Network Lead Academic Participating Site

NCI 国家临床试验网络-网络主导学术参与网站

基本信息

批准号：
9023510
负责人：
LAWRENCE E FLAHERTY
金额：
$ 60.21万
依托单位：
WAYNE STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-25 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9023510
关键词：
Adult Affect American College of Radiology Imaging Network American College of Surgeons Oncology Group Cancer Center Clinical Research Clinical Trials Clinical Trials Cooperative Group Comprehensive Cancer Center Data Disease Enrollment Evaluation Faculty Foundations Funding Goals Gynecologic Oncology Group Institutes Institution Lead Leadership Malignant Neoplasms Manuscripts Minority Minority Recruitment Monitor National Clinical Trials Network National Surgical Adjuvant Breast and Bowel Project Oncology Group Parents Patient Care Patient Education Patients Phase Play Population Positioning Attribute Principal Investigator Protocols documentation Qualifying Radiation Oncology Research Research Design Research Personnel Role Safety Site Solid Southwest Oncology Group System Therapeutic Therapeutic Trials Translations United States Universities Woman abstracting base clinical care meetings melanoma member mortality multidisciplinary novel therapeutics personalized cancer therapy programs public health relevance

项目摘要

DESCRIPTION (provided by applicant): Wayne State University (WSU) - Karmanos Cancer Institute (KCI) has been an active institutional member office cooperative group system since 1972, an NCI designated Comprehensive Cancer Center since 1978, a parent institution Phase I (U01) since 1993, and a member of a Phase 1 consortium (N01) since 2000. We have an active membership in the Southwest Oncology Group (SWOG), Radiation Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) with participation in ACRIN, ACOSOG, NSABP, and Intergroup trials through the CTSU network. We have enrolled over 5,500 patients onto cooperative group clinical trials over the past forty years and over 600 patients have been enrolled onto therapeutic and non-therapeutic trials since 2007, meeting and exceeding accrual goals in a consistent manner. Our Cancer Center is a unique urban based center of research, patient care and education which is reflected in our recruitment of minorities (24%) and women (52%) onto therapeutic cooperative group trials. All adult cooperative group qualifying Phase II and 1 protocol have been submitted through the CIRB for activation since 2009. Over the years, our faculty members have played an important role in both the administrative and scientific functions of the cooperative groups. Presently, six faculty members hold ten key leadership positions. Since 2007, 25 faculty members have been investigators or co-investigators of 121 cooperative group abstracts or manuscripts, and 18 faculty members have been PI or Co-PIs of 43 cooperative group studies. Since our inception, the cancer programs of WSU/KCI have been organized as multidisciplinary disease programs built on the premise that multidisciplinary clinical research and care provides the best treatment option for patients with cancer Accordingly, the translation of ideas into cooperative group proposals and studies and the incorporation of NCI designated high-priority trials into the WSU/KCI treatment priorities have been easily facilitated. NCI funded trials have the highest priority for activation within our institution. Dr. Lawrence Flaherty, a SWOG member since 1988 and the SWOG U-10 PI since 1996 will serve as the PI of this submission. He was the SWOG Melanoma vice Chair from 1990 until 2011 and has been Chair of the SWOG Data Safety and Monitoring Committee since 2011.

描述（由申请人提供）：韦恩州立大学 (WSU) - 卡马诺斯癌症研究所 (KCI) 自 1972 年以来一直是一个活跃的机构成员办公室合作小组系统，自 1978 年以来一直是 NCI 指定的综合癌症中心，是 I 期母机构 (U01)自 1993 年起成为第一阶段联盟 (N01) 的成员，自 2000 年起成为第一阶段联盟 (N01) 的成员。我们是西南肿瘤学小组 (SWOG) 的活跃成员，放射肿瘤学组 (RTOG) 和妇科肿瘤学组 (GOG) 通过 CTSU 网络参与 ACRIN、ACOSOG、NSABP 和组间试验。在过去的四十年里，我们已经招募了超过 5,500 名患者参加合作小组临床试验，自 2007 年以来已经招募了超过 600 名患者参加治疗性和非治疗性试验，以一致的方式达到并超过了应计目标。我们的癌症中心是一个独特的城市研究、患者护理和教育中心，这体现在我们招募少数族裔 (24%) 和女性 (52%) 参加治疗合作小组试验。自 2009 年以来，所有符合第二阶段和第一阶段协议的成人合作小组均已通过 CIRB 提交激活。多年来，我们的教职员工在合作小组的行政和科学职能中发挥了重要作用。目前，六名教员担任十个关键领导职务。自2007年以来，25名教师担任121个合作小组摘要或手稿的研究者或共同研究者，18名教师担任43个合作小组研究的PI或Co-PI。自成立以来，WSU/KCI 的癌症项目一直被组织为多学科疾病项目，其前提是多学科临床研究和护理为癌症患者提供最佳治疗选择。因此，将想法转化为合作小组提案和研究，并将 NCI 指定的高优先级试验纳入 WSU/KCI 治疗优先事项已很容易实现。 NCI 资助的试验在我们机构内具有最高优先级激活权。自 1988 年起成为 SWOG 成员和自 1996 年起成为 SWOG U-10 PI 的 Lawrence Flaherty 博士将担任本次提交的 PI。他从 1990 年至 2011 年担任 SWOG Melanoma 副主席，并自 2011 年起担任 SWOG 数据安全和监测委员会主席。